RU2018101363A3 - - Google Patents

Download PDF

Info

Publication number
RU2018101363A3
RU2018101363A3 RU2018101363A RU2018101363A RU2018101363A3 RU 2018101363 A3 RU2018101363 A3 RU 2018101363A3 RU 2018101363 A RU2018101363 A RU 2018101363A RU 2018101363 A RU2018101363 A RU 2018101363A RU 2018101363 A3 RU2018101363 A3 RU 2018101363A3
Authority
RU
Russia
Application number
RU2018101363A
Other languages
Russian (ru)
Other versions
RU2018101363A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56686850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2018101363(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of RU2018101363A publication Critical patent/RU2018101363A/ru
Publication of RU2018101363A3 publication Critical patent/RU2018101363A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/65—Raman scattering
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G01N24/087—Structure determination of a chemical compound, e.g. of a biomolecule such as a protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2018101363A 2015-07-31 2016-07-27 Кристаллическая форма свободного основания лорлатиниба RU2018101363A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562199418P 2015-07-31 2015-07-31
US62/199,418 2015-07-31
US201662352349P 2016-06-20 2016-06-20
US62/352,349 2016-06-20
PCT/IB2016/054483 WO2017021823A1 (en) 2015-07-31 2016-07-27 Crystalline form of lorlatinib free base

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2020136860A Division RU2852836C1 (ru) 2015-07-31 2016-07-27 Кристаллическая форма свободного основания лорлатиниба

Publications (2)

Publication Number Publication Date
RU2018101363A RU2018101363A (ru) 2019-08-29
RU2018101363A3 true RU2018101363A3 (cg-RX-API-DMAC7.html) 2019-08-29

Family

ID=56686850

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018101363A RU2018101363A (ru) 2015-07-31 2016-07-27 Кристаллическая форма свободного основания лорлатиниба

Country Status (22)

Country Link
US (2) US10420749B2 (cg-RX-API-DMAC7.html)
EP (2) EP3328867B9 (cg-RX-API-DMAC7.html)
JP (1) JP6218253B2 (cg-RX-API-DMAC7.html)
KR (1) KR102088188B1 (cg-RX-API-DMAC7.html)
CN (3) CN107849060A (cg-RX-API-DMAC7.html)
AU (1) AU2016304420B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017028604A2 (cg-RX-API-DMAC7.html)
CA (1) CA2937257C (cg-RX-API-DMAC7.html)
CY (1) CY1123689T1 (cg-RX-API-DMAC7.html)
DK (2) DK3328867T3 (cg-RX-API-DMAC7.html)
ES (2) ES2842302T3 (cg-RX-API-DMAC7.html)
FI (1) FI3798222T3 (cg-RX-API-DMAC7.html)
HK (1) HK1252845A1 (cg-RX-API-DMAC7.html)
HU (2) HUE065536T2 (cg-RX-API-DMAC7.html)
MX (2) MX395263B (cg-RX-API-DMAC7.html)
PL (2) PL3328867T3 (cg-RX-API-DMAC7.html)
PT (2) PT3798222T (cg-RX-API-DMAC7.html)
RU (1) RU2018101363A (cg-RX-API-DMAC7.html)
SG (1) SG10201913200XA (cg-RX-API-DMAC7.html)
SI (2) SI3798222T1 (cg-RX-API-DMAC7.html)
TW (1) TWI616449B (cg-RX-API-DMAC7.html)
WO (1) WO2017021823A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2998885C (en) 2015-09-24 2020-09-01 Cyclenium Pharma Inc. Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same
CA3019905C (en) 2016-04-08 2022-08-23 Pfizer Inc. Crystalline forms of lorlatinib maleate
WO2018232506A1 (en) * 2017-06-22 2018-12-27 Cyclenium Pharma Inc. MACROCYCLIC COMPOUND LIBRARIES CONTAINING PYRIDINE AND METHODS FOR PREPARING AND USING SAME
SI3694863T1 (sl) * 2017-10-10 2023-10-30 Pfizer Inc. Kristalna oblika hidrata proste baze lorlatiniba
US11179412B2 (en) 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
WO2019209633A1 (en) 2018-04-23 2019-10-31 Pliva Hrvatska D.O.O. Solid state forms of lorlatinib and their preparation
CN109232607A (zh) * 2018-09-20 2019-01-18 沈阳药科大学 劳拉替尼的合成方法
CN113260617A (zh) * 2019-01-17 2021-08-13 辉瑞公司 Cdk抑制剂的结晶形式
US12391708B2 (en) 2019-07-18 2025-08-19 Tapi Croatia Industries Ltd Crystalline Lorlatinib : fumaric acid and solid state form thereof
CN110483551B (zh) * 2019-08-30 2021-10-22 北京赛思源生物医药技术有限公司 一种劳拉替尼游离碱的晶体
CN110530998A (zh) * 2019-09-16 2019-12-03 山东省药学科学院 一种劳拉替尼及含劳拉替尼的制剂中有关物质的检测方法
EP4041396A1 (en) 2019-10-10 2022-08-17 Sandoz AG Polymorph of lorlatinib
CN112824417A (zh) * 2019-11-21 2021-05-21 上海天慈国际药业有限公司 一种劳拉替尼的制备方法
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2796967C (en) 2010-05-04 2015-12-01 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
CA2863892C (en) * 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
CA2916605C (en) 2013-06-28 2018-04-24 Pfizer Inc. Solid forms of a macrocyclic kinase inhibitor
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
CA3019905C (en) 2016-04-08 2022-08-23 Pfizer Inc. Crystalline forms of lorlatinib maleate
SI3694863T1 (sl) 2017-10-10 2023-10-30 Pfizer Inc. Kristalna oblika hidrata proste baze lorlatiniba

Also Published As

Publication number Publication date
MX395263B (es) 2025-03-25
US20180235933A1 (en) 2018-08-23
SG10201913200XA (en) 2020-03-30
NZ739304A (en) 2024-11-29
MX382600B (es) 2025-03-13
CN116063323B (zh) 2026-06-30
PT3798222T (pt) 2024-01-22
EP3798222A1 (en) 2021-03-31
CA2937257A1 (en) 2017-01-31
CN116063322A (zh) 2023-05-05
US10420749B2 (en) 2019-09-24
DK3798222T3 (da) 2023-12-11
JP2017039702A (ja) 2017-02-23
WO2017021823A1 (en) 2017-02-09
HUE065536T2 (hu) 2024-05-28
AU2016304420B2 (en) 2019-09-19
CY1123689T1 (el) 2022-03-24
EP3328867B9 (en) 2021-04-14
PT3328867T (pt) 2021-01-13
PL3798222T3 (pl) 2024-03-25
PL3328867T3 (pl) 2021-04-19
TWI616449B (zh) 2018-03-01
JP6218253B2 (ja) 2017-10-25
RU2018101363A (ru) 2019-08-29
MX2018001324A (es) 2018-04-30
HK1252845A1 (zh) 2019-06-06
BR112017028604A2 (pt) 2018-09-04
MX2021002220A (es) 2022-09-01
KR102088188B1 (ko) 2020-03-12
EP3328867B1 (en) 2020-11-11
EP3328867A1 (en) 2018-06-06
HUE052790T2 (hu) 2021-05-28
FI3798222T3 (fi) 2023-11-28
DK3328867T3 (da) 2020-11-16
KR20180022936A (ko) 2018-03-06
SI3328867T1 (sl) 2021-04-30
SI3798222T1 (sl) 2024-02-29
TW201718600A (zh) 2017-06-01
CN107849060A (zh) 2018-03-27
ES2972010T3 (es) 2024-06-10
US20190365712A1 (en) 2019-12-05
EP3798222B1 (en) 2023-11-22
AU2016304420A1 (en) 2018-02-01
CA2937257C (en) 2022-06-14
ES2842302T3 (es) 2021-07-13
US11020376B2 (en) 2021-06-01
CN116063323A (zh) 2023-05-05

Similar Documents

Publication Publication Date Title
BR112018005014A2 (cg-RX-API-DMAC7.html)
AU2022228198B1 (cg-RX-API-DMAC7.html)
CN303074418S (zh) 筷子(hy204)
CN303074134S (zh) 铜棺
CN303070228S (zh) 笔(tgb17080)
CN303069685S (zh) 手机支架(hl-66)
CN303071150S (zh) 加湿空气净化器
CN303071511S (zh) 推拉窗型材(玻璃扇)
CN303069284S (zh) 机动车扬声器
CN303063389S (zh) 化妆盒(sf-27)
CN303066652S (zh) 焊枪手柄(六)
CN303069527S (zh) 带有3d人偶相机拍照界面的手机
CN303069099S (zh) 塑壳断路器(电动型)
CN303067884S (zh) 分析物测量仪
BE2015C047I2 (cg-RX-API-DMAC7.html)
BE2015C044I2 (cg-RX-API-DMAC7.html)
BR0003686B1 (cg-RX-API-DMAC7.html)
BR0003751B1 (cg-RX-API-DMAC7.html)
BR0009942B1 (cg-RX-API-DMAC7.html)
BR0007487B1 (cg-RX-API-DMAC7.html)
BR0000695B1 (cg-RX-API-DMAC7.html)
BR0000126B1 (cg-RX-API-DMAC7.html)
BR0009649B1 (cg-RX-API-DMAC7.html)
BR0002874B1 (cg-RX-API-DMAC7.html)
BR0007747B1 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
HE9A Changing address for correspondence with an applicant